Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

Age-Related Macular Degeneration | Synapse

January 9, 2024Open Access

Age-Related Macular Degeneration

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The prevalence of AMD is anticipated to increase worldwide to 288 million individuals by 2040. Intravitreally administered anti-VEGF treatment is first-line therapy for exudative neovascular AMD.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Fleckenstein et al. (Tue,) studied this question.

synapsesocial.com/papers/69d5763bc928a9acfd89a415 https://doi.org/https://doi.org/10.1001/jama.2023.26074

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis2015 · 180 citations
2Complement Factor H Polymorphism and Age-Related Macular Degeneration2005 · 2,449 citations
3Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective2019 · 49 citations
4Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials2022 · 692 citations
5Characterizing Disease Burden and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration2018 · 116 citations